CRBN and systemic lupus erythematosus: Among these drugs, iberdomide (CC-220) is a novel compound with the highest reported specificity for CRBN and the lowest IC50, currently in a phase 2 clinical trial for systemic lupus erythematosus (SLE) and multiple myeloma (MM).